Loading
Tests whether a two-armed antibody against EGFR and a stem-cell marker can lift first-line immunotherapy results in head and neck cancer.
Phase 2 petosemtamab + pembrolizumab reported ORR ~63% in first-line PD-L1-positive HNSCC (ASCO 2025), far above pembrolizumab's historical ~19-23%. LiGeR-HN1 (first line, includes HPV-positive disease) and LiGeR-HN2 (second line, monotherapy vs chemotherapy) are the registrational trials; interim analyses expected 2026-27.
Shares Petosemtamab, Genmab, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies.
Shares EGFR-directed bispecific + PD-1 blockade, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, EGFR.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares EGFR-directed bispecific + PD-1 blockade, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, EGFR.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, Head and neck squamous cell carcinoma, Pembrolizumab.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Pembrolizumab.